Loading
A phase 3 trial testing HRS-8080 in HR-positive / HER2-negative breast cancer, now recruiting.
A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer is a phase 3 interventional study registered as NCT07024173, led by Shandong Suncadia Medicine, and recruiting on the registry. Official title: A Multicenter, Open-label, Randomised Controlled Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer With Disease Progression After Previous Endocrine Therapy. Planned enrolment is 240 participants (estimated). The study started in 2025-07-23 and primary completion is expected in 2026-12. No results have been posted on ClinicalTrials.gov.
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals, HR-positive / HER2-negative breast cancer.
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals, HR-positive / HER2-negative breast cancer.
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals.
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals.
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals.
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals.
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals.
Shares Jiangsu Hengrui Pharmaceuticals, HR-positive / HER2-negative breast cancer.